Breast Cancer

Show only recruiting trials?

Roche.png

MAC19

Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

Status

Recuiting

JCP

17-123

NCT

NCT01901094

Roche.png

AMEERA-5 | EFC15935

A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease

Status

Recruiting

JCP

JCP094

NCT

NCT04478266

Roche.png

B-59

Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

Status

Recruiting

JCP

JBG-1801

NCT

NCT03281954

Roche.png

BO41843

A Study Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Status

Recruiting

JCP

JCP084

NCT

NCT04546009

Roche.png

CAPTUR | PM.1

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | A Phase II Basket Trial

Status

Recruiting

JCP

PM.1

NCT

NCT03297606

Roche.png

CheckMate 7FL

A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

Status

Recruiting

JCP

NCT

NCT04109066

Roche.png

KeyLynk-009

Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)

Status

Recruiting

JCP

NCT

NCT04191135

Roche.png

MAC24

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Status

Recruiting

JCP

NCT

NCT02954874

Roche.png

MK-3475-756

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Status

Recruiting

JCP

JGB-1806

NCT

NCT03725059

Roche.png

MK-7339-009

Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)

Status

Recruiting

JCP

NCT

NCT04191135

Roche.png

NRG-BR003

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Status

Recruiting

JCP

NCT

NCT02488967

Roche.png

RUBY

A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature

Status

Recruiting

JCP

NCT

NCT02505048

Roche.png

SERENA 2 | D8530C00002

A Comparative Study of AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer (SERENA-2)

Status

Recruiting

JCP

JCP079

NCT

NCT04214288

Roche.png

SGNTUC-016

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Status

Recruiting

JCP

JCP086

NCT

NCT03975647

Roche.png

SMX 18-001

An Open-label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2− Breast Cancer with an ESR1 Mutation

Status

Recruiting

JCP

JCP087

NCT

NCT03781063

Roche.png

TAD

Targeted Axillary Dissection (TAD) in Early-stage Node Positive Breast Cancer (TADEN)

Status

Recruiting

JCP

NCT

NCT04671511

Roche.png

WO41554

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GDC-0077 plus Palbociclib and Fulvestrant versus Placebo plus Palbociclib and Fulvestrant in Patients with PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (INAVO120)

Status

Recruiting

JCP

JCP088

NCT

NCT04191499

Roche.png

Kate 3

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

Status

Opening soon

JCP

NCT

NCT04740918

Roche.png

LALEAST

Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer

Status

Opening soon

JCP

NCT

NCT03917082

Roche.png

SERENA 4

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease.

Status

Opening soon

JCP

NCT

NCT04711252

Roche.png

CheckMate 7A8

A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer

Status

Opening Soon

JCP

NCT

NCT04075604

Roche.png

CO41012 | IPATunity150

A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer (IPATunity150)

Status

Opening Soon

JCP

JCP080

NCT

NCT04060862

Roche.png

D9670C00001 | Destiny-Breast06 (DB-06)

A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)

Status

Opening Soon

JCP

Pending

NCT

NCT04494425

Roche.png

Destiny 5 (B60)

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy

Status

Opening Soon

JCP

NCT

NCT04622319

Roche.png

EPIK-B2 | CYBL719G12301

Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

Status

Opening Soon

JCP

JCP075

NCT

NCT04208178

Roche.png

AMEERA-3 | ACT16105

Phase 2 Study of SAR439859 Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)

Status

Closed to Accrual

JCP

JCP067

NCT

NCT04059484

Roche.png

CO40016

A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (IPATunity130)

Status

Closed to Accrual

JCP

JCP031

NCT

NCT03337724

Roche.png

CPDR001X2X01B

Rollover Study for Continued Safety and Tolerability in Subjects Treated with Spartalizumab Alone or in Combination With Other Study Treatments

Status

Closed to Accrual

JCP

JCP069

NCT

NCT04058756

Roche.png

CheckMate 848

A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) (CheckMate 848)

Status

Closed to Accrual

JCP

JCP052

NCT

NCT03668119

Roche.png

FALCON | D699BC00001

A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer

Status

Closed to Accrual

JCP

McG1227

NCT

NCT01602380

Roche.png

MA.32

Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32

Status

Closed to Accrual

JCP

MA32

NCT

NCT01286233

Roche.png

MAC.12 | TAILORx

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) (TAILORx)

Status

Closed to Accrual

JCP

MAC.12

NCT

NCT00310180

Roche.png

MAC.15 | RxPONDER

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Status

Closed to Accrual

JCP

MAC.15

NCT

NCT01272037

Roche.png

MONARCH 3 (15417 | I3Y-MC-JPBM)

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (MONARCH 3)

Status

Closed to Accrual

JCP

JPBM

NCT

NCT02246621

Roche.png

NATALEE-TRIO033

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

Status

Closed to Accrual

JCP

NCT

NCT03701334

Filter Clinical Trials by:

arrow&v
arrow&v
arrow&v
arrow&v

Biomarkers:

No trials match your search criteria